Heidi Overton Nominated for FDA Commissioner: What It Means for Peptide Compounding and the 503A Bulks List

President Donald Trump announced Wednesday (Aug 19, 2026) that he is nominating Dr. Heidi Overton, deputy director of the White House Domestic Policy Council, to lead the FDA. “Dr. Heidi has been a ROCKSTAR in my Administration,” Trump posted. “We need her leadership at the FDA now to ensure that the U.S. remains the WORLD LEADER for Scientific Discovery and CURES.”

The timing matters across the peptide space: the incoming commissioner — if confirmed — inherits the most consequential peptide decisions in a decade. As AP put it, “One major decision for the next commissioner is what to do about peptide regulation.”

Who is Heidi Overton?

Overton is a physician (University of New Mexico School of Medicine; Johns Hopkins doctorate; board-certified in public health) and former chief policy officer of the America First Policy Institute. Her public record sits almost entirely outside drug regulation: she stood beside Trump at the Aug 10 vaccine order signing that cut the recommended childhood schedule from 18 shots to 11, and has described mifepristone as “teleabortion,” urging strict regulation “to protect women and children.”

One fact is worth stating plainly: no public statements from Overton on peptide compounding, the 503A/503B lists, or GLP-1 policy have been found. Until she speaks in hearings, anyone claiming she will expand or restrict compounding is speculating.

A leaderless agency, a third choice

The FDA has had no Senate-confirmed leader since Marty Makary resigned in May. Politico described his tenure as “marked by mass layoffs, persistent churn among senior leaders and policy fights with lawmakers, drugmakers and Trump.” Senior exits continued: vaccine and biotech chief Vinay Prasad stepped down in April, and acting drug-center director Tracy Beth Hoeg was replaced.

Overton is Trump’s third choice: acting commissioner Kyle Diamantas declined the job, as did former Rep. Brad Wenstrup (R-Ohio); Diamantas continues leading the agency in an acting capacity. If she stalls, the decisions land on an acting commissioner’s desk — they don’t wait for a confirmed leader.

Where peptide policy stands right now (confirmed)

Three events in the past five months set the baseline:

• April 15, 2026 — the reclassification. The FDA moved 12 therapeutic peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, Epitalon, GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF — out of Category 2, the “pending nomination with safety concerns” tier that had frozen compounding. BPC-157 and TB-500 — on the high-risk list since 2023 — were removed from it earlier this year under HHS Secretary Robert F. Kennedy Jr., a self-described “big fan” of peptides. Licensed 503A pharmacies can now legally prepare these peptides under valid patient-specific prescriptions. This does not make them FDA-approved, and it does not legalize the gray-market research-chemical channel. Full breakdown: the April 15 reclassification.
• July 23–24, 2026 — the PCAC vote. The Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend six peptides — BPC-157, TB-500, KPV, MOTS-c, epitalon, and semax — for the compounding-safety (503A) bulks list, and rejected a seventh, emideltide, by a 6–7 vote. FDA staff noted there are no human studies of TB-500, and the panel was stocked with industry members. The votes are recommendations only: formal 503A placement requires rulemaking that could take months or years, with an enforcement-discretion policy the likely near-term path. See the PCAC July 2026 tracker and our preview of the possible outcomes.
• The 503A stakes. A final bulks-list placement would let licensed compounding pharmacies distribute these peptides at scale under prescription — the line between the legal compounding channel and everything outside it. Compounders have been positioning for months, building capacity and re-credentialing across states, while state boards layer their own requirements on top of the federal floor. Our BPC-157 and TB-500 guides cover each peptide’s actual status.

The enforcement posture Overton would inherit

FDA enforcement against compounders has been intensifying all year: roughly 30 warning letters hit the compounded GLP-1 supply chain in early March, and a Hims & Hers facility drew a citation over insect contamination in February. The actions span 503A and 503B pharmacies alike — enforcement roundup.

The adjacent GLP-1 fight shows how the bulks-list mechanism doubles as an enforcement lever. On April 30, the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, “finding no clinical need for outsourcing facilities to compound these drugs from bulk substances.” The comment period, extended to July 30, 2026, has closed — no final determination yet, and that call sits on the next commissioner’s desk. Analysts expect more of the same: “Industry will view this pick as extremely troublesome and FDA career staff will continue to flee the agency,” Raymond James analyst Chris Meekins told Axios. “Any progress made since Makary’s departure is likely to be immediately reversed if she is confirmed.”

What a new commissioner could mean (speculation, flagged)

None of the following is established policy. If confirmed, her FDA faces three open questions:

1. The 503B GLP-1 exclusion. Finalize, modify, or shelve it — setting precedent for how the “clinical need” standard applies to peptides with thinner evidence.
2. Converting the PCAC recommendations into the 503A bulks list. Rulemaking, enforcement discretion first, or slow-walk — each moves the market differently.
3. Enforcement tempo and staffing. Warning letters already flow; a more aggressive commissioner — or a career staff that keeps leaving — changes how fast anything gets decided.

The permissive signals are real — the April 15 reclassification, the PCAC votes, Kennedy’s own enthusiasm for peptides. But the enforcement machinery points the other way, and the “clinical need” logic used against GLP-1s “applies even more forcefully to peptides with thinner evidence,” a compliance consultant told PeptidesBeat in May. Overton’s own views are unknown — both outcomes remain on the table.

While the next commissioner is chosen, Novo has formally asked the FDA to add semaglutide to the DDC lists — analysis: Compounded GLP-1 Ban: Novo and Lilly’s FDA Push Explained.

Confirmation is far from certain

No hearing date has been set, and the announcement may not yet be a formal Senate submission. Senate HELP Committee chair Bill Cassidy has written that Overton’s record “alone is almost disqualifying,” and Republicans hold a one-member committee majority — a single defection could sink the nomination. She is the third person offered the job.

Bottom line for researchers, sellers, and practitioners

1. Nothing changes today. The nomination alters no current rule. The baseline: 12 peptides in the interim evaluation tier, compoundable by licensed 503A pharmacies under patient-specific prescriptions; gray-market sales stay outside the legal supply chain.
2. Watch three signals: (a) confirmation hearings and any Overton statements on compounding; (b) FDA action on the 503B exclusion; (c) FDA follow-through on the PCAC recommendations.
3. Keep compliance conservative. Warning letters are already landing and the bulks-list outcome is unresolved — don’t build on a legal status a final rule could remove.
4. Don’t over-read the politics. A peptide-friendly HHS and a pro-compounding panel vote coexist with aggressive enforcement — every concrete prediction is speculation until the Senate acts.

The one-line takeaway: Overton’s nomination puts the FDA commissioner’s seat in play just as peptide policy reaches its most consequential moment — but with no public position from Overton on peptides, no hearing date, and a razor-thin confirmation margin, the 503A decision gets made in the Senate and the rulemaking docket, not by the announcement.